Table 3.
The relationships of NRI with pathological parameters.
| Parameter | Level | Overall | Low NRI | High NRI | p |
|---|---|---|---|---|---|
| n | 202 | 75 | 127 | ||
| TLN (%) | ≤28 | 98 (48.5) | 27 (36.0) | 71 (55.9) | 0.010* |
| >28 | 104 (51.5) | 48 (64.0) | 56 (44.1) | ||
| PLN (%) | ≤6 | 101 (50.0) | 31 (41.3) | 70 (55.1) | 0.081 |
| >6 | 101 (50.0) | 44 (58.7) | 57 (44.9) | ||
| HER2 (%) | Negative | 189 (93.6) | 66 (88.0) | 123 (96.9) | 0.029* |
| Positive | 13 (6.4) | 9 (12.0) | 4 (3.1) | ||
| CK (%) | Negative | 25 (12.4) | 8 (10.7) | 17 (13.4) | 0.729 |
| Positive | 177 (87.6) | 67 (89.3) | 110 (86.6) | ||
| Vimentin (%) | Negative | 189 (93.6) | 71 (94.7) | 118 (92.9) | 0.846 |
| Positive | 13 (6.4) | 4 (5.3) | 9 (7.1) | ||
| VEGF (%) | Negative | 171 (84.7) | 62 (82.7) | 109 (85.8) | 0.689 |
| Positive | 31 (15.3) | 13 (17.3) | 18 (14.2) | ||
| CD56 (%) | Negative | 201 (99.5) | 75 (100.0) | 126 (99.2) | 1.000 |
| Positive | 1 (0.5) | 0 (0.0) | 1 (0.8) | ||
| CD31 (%) | Negative | 173 (85.6) | 61 (81.3) | 112 (88.2) | 0.256 |
| Positive | 29 (14.4) | 14 (18.7) | 15 (11.8) | ||
| CD34 (%) | Negative | 110 (54.5) | 42 (56.0) | 68 (53.5) | 0.847 |
| Positive | 92 (45.5) | 33 (44.0) | 59 (46.5) | ||
| D2-40 (%) | Negative | 127 (62.9) | 44 (58.7) | 83 (65.4) | 0.424 |
| Positive | 75 (37.1) | 31 (41.3) | 44 (34.6) | ||
| S100 (%) | Negative | 32 (15.8) | 8 (10.7) | 24 (18.9) | 0.177 |
| Positive | 170 (84.2) | 67 (89.3) | 103 (81.1) |
TLN, total lymph nodes; PLN, positive lymph nodes; HER2, human epidermal growth factor receptor; CK, Cytokeratin; VEGF, vascular endothelial growth factor; CD56, Cluster of Differentiation 56; CD31, Cluster of Differentiation 31; CD34, Cluster of Differentiation 34. * With statistical differences (P < 0.05).